Want to see ANRO full AI Analyst Report?

Alto Neuroscience, Inc. (ANRO) Price & Analysis

571 Followers

ANRO Stock Chart & Stats

$35.13

$1.09(4.07%)

At close: Jul 27 4:00 PM EDT

$35.13

$1.09(4.07%)

Day’s Range― - ―

52-Week Range$3.41 - $37.48

Previous Close$27.8

Volume499.76K

Average Volume (3M)437.24K

Market Cap

$1.39B

Enterprise Value$909.40

Total Cash (Recent Filing)$243.73M

Total Debt (Recent Filing)$7.05M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Mar 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.48

Shares Outstanding39,242,104

10 Day Avg. Volume446,962

30 Day Avg. Volume437,235

Financial Highlights & Ratios

PEG Ratio0.66

Price to Book (P/B)3.40

Price to Sales (P/S)0.00

P/FCF Ratio-9.92

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$44.00

Price Target Upside25.25% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.78

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet And Low LeverageLow leverage and positive equity provide financial flexibility while Alto funds clinical development. The substantial asset base reduces immediate balance-sheet stress, although it does not eliminate the need to finance ongoing research and development.

Liquidity Supports Late-stage Clinical DevelopmentSignificant liquidity gives Alto capacity to advance ALTO-207 through expanded Phase 3 testing without relying solely on near-term capital markets. This extends development runway and supports continuity for its lead clinical program.

Biomarker-driven Precision Medicine StrategyPatient stratification may improve trial design, identify responsive populations and differentiate Alto’s neuroscience programs. A biomarker-led approach can strengthen development efficiency and commercial positioning if clinical results validate the selected subgroups.

Bears Say

No Meaningful Commercial RevenueWith no established commercial product revenue, Alto remains dependent on clinical milestones and external financing rather than recurring operating income. This leaves future economics contingent on successful development, regulatory approval and eventual market adoption.

Widening Losses And Persistent Cash BurnSustained operating and free-cash-flow losses consume the capital base and require continued funding for trials. Even with liquidity, prolonged burn can shorten runway, constrain strategic flexibility and increase dependence on successful clinical execution.

Clinical And Financing DependenceThe business is concentrated on advancing investigational assets, particularly ALTO-207, so value creation depends on trial outcomes and regulatory progress. Equity funding also introduces dilution and signals that internal cash generation cannot yet support development.

Alto Neuroscience, Inc. News

Alto Neuroscience names Nick Smith president, CFO

Alto Neuroscience (ANRO) announced the promotion of Nick Smith to president and chief financial officer, effective August 26,...

6d ago

ANRO

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Alto Neuroscience (ANRO) to $55 from $50 and keeps a...

16d ago

ANRO

Alto Neuroscience reports Q EPS (65c), consensus (77c)

“The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,”...

16d ago

ANRO

Alto Neuroscience price target raised to $37 from $28 at BTIG

BTIG analyst Thomas Shrader raised the firm’s price target on Alto Neuroscience (ANRO) to $37 from $28 and...

16d ago

ANRO

Alto Neuroscience price target raised to $37 from $33 at BofA

BofA raised the firm’s price target on Alto Neuroscience (ANRO) to $37 from $33 and keeps a Buy...

17d ago

ANRO

Alto Neuroscience Promotes Smith to President, CFO

Alto Neuroscience, Inc. ( ($ANRO) ) has provided an announcement. On August 26, 2026, Alto Neuroscience’s board promoted...

6d ago

ANRO

Alto Neuroscience Lawsuit Dismissed for Now, With Investors Given Chance to Amend Claims

A federal judge in California has, for now, dismissed a securities lawsuit against Alto Neuroscience, Inc. (NYSE: ANRO)...

12d ago

ANRO

Analyst Lifts ALTO-207 Price Target to $37 on Strong TRD Profile and Expanded Monotherapy Strategy, Reiterates Buy

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Alto Neuroscience, Inc.. The associated price target...

20d ago

ANRO

Alto Neuroscience Raises Capital to Advance ALTO-207

Alto Neuroscience, Inc. ( ($ANRO) ) has issued an update. On July 13, 2026, Alto Neuroscience entered into...

2M ago

ANRO

Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials

Alto Neuroscience, Inc. ( ($ANRO) ) has provided an announcement. On July 13, 2026, Alto Neuroscience, Inc. reported...

2M ago

ANRO

Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering

Alto Neuroscience (ANRO) announced the pricing of an underwritten registered direct offering of 3,776,436 shares of its common...

2M ago

ANRO

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

Alto Neuroscience (ANRO) highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of...

3M ago

ANRO

Alto Neuroscience Appoints Andrew Miller to Board

Alto Neuroscience, Inc. ( ($ANRO) ) just unveiled an announcement. On May 27, 2026, Alto Neuroscience, Inc. expanded...

3M ago

ANRO

Alto Neuroscience appoints Miller to Board of Directors

Alto Neuroscience (ANRO) announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27,...

3M ago

ANRO

ANRO FAQ

What was Alto Neuroscience, Inc.’s price range in the past 12 months?

Alto Neuroscience, Inc. lowest stock price was $3.41 and its highest was $37.48 in the past 12 months.

What is Alto Neuroscience, Inc.’s market cap?

Alto Neuroscience, Inc.’s market cap is $1.39B.

When is Alto Neuroscience, Inc.’s upcoming earnings report date?

Alto Neuroscience, Inc.’s upcoming earnings report date is Mar 24, 2027 which is in 203 days.

How were Alto Neuroscience, Inc.’s earnings last quarter?

Alto Neuroscience, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.085.

Is Alto Neuroscience, Inc. overvalued?

According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alto Neuroscience, Inc. pay dividends?

Alto Neuroscience, Inc. does not currently pay dividends.

What is Alto Neuroscience, Inc.’s EPS estimate?

Alto Neuroscience, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alto Neuroscience, Inc. have?

Alto Neuroscience, Inc. has 39,242,104 shares outstanding.

What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?

Alto Neuroscience, Inc. reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went up 10.692%.

Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?

Currently, no hedge funds are holding shares in ANRO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alto Neuroscience, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

60.93%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Alto Neuroscience, Inc. (ANRO) Earnings & Revenues

Historic Earnings Reports

ANRO Stock 12 Month Forecast

Average Price Target

$44.00

▲(25.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","56":"$56","15.5":"$15.5","42.5":"$42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,15.5,29,42.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,29.21846153846154,31.36692307692308,33.51538461538462,35.66384615384615,37.8123076923077,39.96076923076923,42.10923076923077,44.25769230769231,46.40615384615385,48.55461538461539,50.70307692307692,52.85153846153847,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,28.372307692307693,29.674615384615386,30.97692307692308,32.27923076923077,33.581538461538464,34.88384615384616,36.18615384615384,37.488461538461536,38.79076923076923,40.09307692307692,41.395384615384614,42.69769230769231,{"y":44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,27.833846153846153,28.59769230769231,29.361538461538462,30.125384615384615,30.88923076923077,31.653076923076924,32.41692307692308,33.18076923076923,33.94461538461538,34.708461538461535,35.472307692307695,36.23615384615385,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.63,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >